Tocilizumab monotherapy uncovered the role of the CCL22/17-CCR4⁺ Treg axis during remission of crescentic glomerulonephritis

Medicine and Dentistry

• Tocilizumab 100%
• Cytokine 83%
• Kidney 66%
• Glomerulonephritis 66%
• Macrophage 66%
• Spontaneous Remission 50%
• Drug 33%
• Inpatient 33%
• Chemotherapeutic Agent 33%
• Serum 33%
• ANCA Associated Vasculitis 33%
• Monotherapy 33%
• Chemokine 33%
• Serositis 16%
• Patient 16%
• Diseases 16%
• Lymph Node 16%
• Monoclonal Antibody 16%
• Autoimmunity 16%
• Nephropathy 16%
• Autoimmune Disease 16%
• Peripheral Blood Mononuclear Cell 16%
• Thymus and Activation Regulated Chemokine 16%
• Macrophage Derived Chemokine 16%
• Interleukin 6 Receptor 16%

Immunology and Microbiology

• Regulatory T Cell 100%
• Tocilizumab 100%
• Kidney 66%
• Interleukin Derivative 66%
• Glomerulonephritis 66%
• CCL22 66%
• ANCA Associated Vasculitis 33%
• CCR4 33%
• Inflammation 16%
• Blood Level 16%
• Interleukin-6 Receptor 16%
• Monoclonal Antibodies 16%
• Autoimmune Disease 16%
• Auto-immunity 16%
• Peripheral Blood Mononuclear Cell 16%
• Thymus and Activation Regulated Chemokine 16%
• Experimental Model 16%
• Macrophage Derived Chemokine 16%
• CD11c 16%